Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 10, 2023
Data Byte
Translational spotlight on Alzheimer's targets
Academic studies identify clusters of new Alzheimer’s targets that modulate tauopathy and microglia, plus mechanisms including ATP metabolism
BioCentury | Feb 10, 2022
Discovery & Translation
Translational trendspotting: a Distillery dive into neurology
Highlights include a new approach to the amyloid hypothesis, white space strategies for stroke and gene therapies
BioCentury | Apr 7, 2021
Distillery Therapeutics
RECK, an inhibitor of amyloid precursor protein cleavage, as a target for Alzheimer’s
DISEASE CATEGORY: Neurology
INDICATION: Alzheimer’s disease Blocking RECK, a membrane-tethered inhibitor of APP-cleaving enzyme ADAM10, could treat Alzheimer’s disease. Levels of
INDICATION: Alzheimer’s disease Blocking RECK, a membrane-tethered inhibitor of APP-cleaving enzyme ADAM10, could treat Alzheimer’s disease. Levels of
Items per page:
1 - 3 of 3